

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5826255

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
SEQUENCE:	2
CONVEYING PARTY DATA	
Name	Execution Date
BANK OF AMERICA, N.A., AS COLLATERAL AGENT	11/15/2019
RECEIVING PARTY DATA	
Name:	GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
Street Address:	2410 LILLYVALE AVENUE
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514
Name:	GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.)
Street Address:	2410 LILLYVALE AVENUE
Internal Address:	C/O GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514
Name:	GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.)
Street Address:	5555 VALLEY BOULEVARD
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032
Name:	BIOMAT USA, INC.
Street Address:	2410 LILLYVALE AVENUE
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514
Name:	GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Street Address:	4560 HORTON STREET
City:	EMERYVILLE
State/Country:	CALIFORNIA
Postal Code:	94608-2916

PATENT

Name:	GRIFOLS WORLDWIDE OPERATIONS USA, INC.
Street Address:	1311 TEMPLE AVENUE
City:	CITY OF INDUSTRY
State/Country:	CALIFORNIA
Postal Code:	91746-1510
Name:	GRIFOLS USA, LLC
Street Address:	2410 LILLYVALE AVENUE
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90032-3514

PROPERTY NUMBERS Total: 65

Property Type	Number
Patent Number:	5319072
Patent Number:	5356878
Patent Number:	5399670
Patent Number:	5288853
Patent Number:	5561108
Patent Number:	5688912
Patent Number:	5723579
Patent Number:	5844087
Patent Number:	6037452
Patent Number:	6121422
Patent Number:	6693173
Patent Number:	5286849
Patent Number:	5659017
Patent Number:	6566504
Patent Number:	5744586
Patent Number:	6162904
Patent Number:	5561115
Patent Number:	5610285
Patent Number:	5783663
Patent Number:	5831003
Patent Number:	5911165
Patent Number:	5985836
Patent Number:	6355243
Patent Number:	6462180
Patent Number:	6964764
Patent Number:	6969515

Property Type	Number
Patent Number:	7544500
Patent Number:	7871608
Patent Number:	8075175
Patent Number:	8231869
Patent Number:	8852585
Patent Number:	8560246
Patent Number:	8101394
Patent Number:	8772461
Patent Number:	8617863
Patent Number:	9206410
Patent Number:	8596326
Patent Number:	8759293
Patent Number:	8648177
Patent Number:	8840637
Patent Number:	9121857
Patent Number:	9273366
Patent Number:	9512493
Patent Number:	8182808
Patent Number:	8034913
Patent Number:	8268782
Patent Number:	8420079
Patent Number:	8512980
Patent Number:	6391298
Patent Number:	8232369
Patent Number:	6984492
Patent Number:	6521226
Patent Number:	9290820
Application Number:	12741030
Application Number:	14819001
Application Number:	14926450
Application Number:	13761684
Application Number:	15161931
Application Number:	14803416
Application Number:	14294460
Application Number:	14221341
Application Number:	15312365
Application Number:	12724032
Application Number:	14288691

Property Type	Number
Application Number:	62442134

CORRESPONDENCE DATA

Fax Number: (202)835-7586
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-835-7500
Email: dcip@milbank.com
Correspondent Name: JAVIER J. RAMOS
Address Line 1: 1850 K STREET, NW, SUITE 1100
Address Line 2: MILBANK, LLP
Address Line 4: WASHINGTON, D.C. 20006

ATTORNEY DOCKET NUMBER:	27465.00047
NAME OF SUBMITTER:	JAVIER J. RAMOS
SIGNATURE:	/Javier J. Ramos/
DATE SIGNED:	11/18/2019

Total Attachments: 8
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page1.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page2.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page3.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page4.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page5.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page6.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page7.tif
source=8. Grifols 2019 -- Release of Security Interest in Patents (Executed) - BOFA#page8.tif

Release of Security Interest in Patents

This **Release of Security Interest in Patents**, dated as of November 15, 2019 (this "Release"), is made by BANK OF AMERICA, N.A., as collateral agent for the Secured Parties (in such capacity, the "Collateral Agent") in favor of GRIFOLS SHARED SERVICES NORTH AMERICA, INC., a Virginia corporation, GRIFOLS THERAPEUTICS LLC (formerly known as Grifols Therapeutics, Inc.), a Delaware limited liability company, GRIFOLS BIOLOGICALS LLC (formerly known as Grifols Biologicals, Inc.), a Delaware limited liability company, BIOMAT USA, INC., a Delaware corporation, GRIFOLS DIAGNOSTIC SOLUTIONS INC., a Delaware corporation, GRIFOLS WORLDWIDE OPERATIONS USA, INC., a Delaware corporation, and GRIFOLS USA, LLC, a Florida limited liability company (each a "Grantor" and collectively the "Grantors"). For purposes of this Release, the "Secured Parties" shall have the meaning assigned in that certain U.S. Pledge and Security Agreement, dated as of January 31, 2017 entered into by the Grantors in favor of the Collateral Agent (as amended, restated, or modified from time to time).

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of January 31, 2017 (as amended, restated, or modified from time to time, the "Patent Security Agreement"), which Patent Security Agreement was recorded with the United States Patent and Trademark Office on February 7, 2017 at Reel 041651 Frame 0487, the Grantors granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantors right, title and interest in, to and under the Patent Collateral (as defined in the Patent Security Agreement), including, without limitation those patents listed on Schedule I hereto; and

WHEREAS, the Grantors have requested the Collateral Agent to release, discharge, terminate and cancel its lien on and security interest in and to the Patent Collateral (as defined in the Patent Security Agreement), including, without limitation, the patents set forth on Schedule I hereto;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Collateral Agent, on behalf of the Secured Parties, does hereby consent and agree as follows:

The Collateral Agent, on behalf of the Secured Parties, their successors, legal representatives and assigns, hereby unconditionally and irrevocably (a) releases, discharges, terminates and cancels any and all of its security interest in and to the Patent Collateral (as defined in the Patent Security Agreement), including, without limitation, all United States issuances and applications for any of the following: patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application listed or required to be listed in Schedule I attached hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all patentable inventions and improvements thereto, (iv) all rights to sue or otherwise recover for any past, present and future infringement or other violation thereof, (v) all proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages, and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world, (b) agrees that any and all right, title and interest of the Collateral Agent in, to or under the Patent

[Release of Security Interest in Patents]

Collateral (as defined in the Patent Security Agreement) shall hereby terminate, cease and become void, and (c) assigns, transfers and conveys to the Grantors any and all right, title and interest it may have in, to and under the Patent Collateral (as defined in the Patent Security Agreement).


The Collateral Agent authorizes and requests that the Commissioner for Patents of the United States Patent and Trademark Office, and any other applicable government officer or authority, record this Release.

The Collateral Agent agrees to take all further actions, and provide the Grantors with any information, cooperation and assistance, including, without limitation, the execution and delivery of any and all further instruments, authorizations, documentation and release forms as any Grantor or its successor, assign or legal representative may reasonably request to confirm, effectuate and record this Release and the termination, cancellation and release of the security interest and any right, title or interest of the Collateral Agent in, to or under the Patent Collateral (as defined in the Patent Security Agreement) at Grantors' sole cost and expense.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature page follows]

**BANK OF AMERICA, N.A., AS COLLATERAL
AGENT**

By: 
Name: _____
Title: Angela Larkin
Vice President

[Release of Security Interest in Patents]

Schedule I

Attached hereto

Title	Application No.	Filing Date	Patent No. / Pub No.	Issue Date / Pub Date
HUMAN ANTITHROMBIN-III PREPARATION	07818831	01/10/1992	5319072	06/07/1994
GEL FILTRATION OF FACTOR VIII	08000852	01/04/1993	5356878	10/18/1994
SOLUBILIZATION AND STABILIZATION OF FACTOR VIII COMPLEX	08054903	04/29/1993	5399670	03/21/1995
FACTOR VIII PURIFICATION PROCESS	07876410	4/30/1992	5,288,853	2/22/1994
PREPARATION OF ALPHA-1-ANTICHYMOTRYPSIN	08282860	07/29/1994	5561108	10/01/1996
PEPTIDE LIGANDS WHICH BIND TO VON WILLEBRAND FACTOR	08537069	09/22/1995	5688912	11/18/1997
FIBRINOGEN BINDING PEPTIDES	08595718	02/02/1996	5723579	03/03/1998
METHOD AND DEVICE FOR DELIVERING FIBRIN GLUE	08744488	11/05/1996	5844087	12/01/1998
POLY(ALKYLENE OXIDE)-FACTOR VIII OR FACTOR IX CONJUGATE	07866518	04/10/1992	6037452	03/14/2000
METHOD AND DEVICE FOR DELIVERING FIBRIN GLUE	09200636	11/25/1998	6121422	09/19/2000
METHOD TO REMOVE CITRATE AND ALUMINUM FROM PROTEINS	09805397	03/13/2001	6693173	02/17/2004
PURIFICATION OF FACTOR IX	07913666	7/14/1992	5,286,849	2/15/1994
ANION EXCHANGE PROCESS FOR THE PURIFICATION OF FACTOR VIII	08554724	11/7/1995	5,659,017	8/19/1997
PROCESS FOR VIRAL INACTIVATION OF LYOPHILIZED BLOOD PROTEINS	09894346	6/28/2001	6,566,504	5/20/2003
MANUFACTURING PROCESS FOR THE PRODUCTION OF PURIFIED TRANSFERRIN	08668351	6/26/1996	5,744,586	4/28/1998
MANUFACTURING METHOD FOR INTRAVENOUSLY ADMINISTRABLE IMMUNE GLOBULIN AND RESULTANT PRODUCT	09421405	10/21/1999	6,162,904	12/19/2000
LOW TEMPERATURE ALBUMIN FRACTIONATION USING SODIUM CAPRYLATE AS A PARTITIONING AGENT	08288180	8/10/1994	5,561,115	10/1/1996
PURIFICATION OF ALPHA-1 PROTEINASE INHIBITOR USING NOVEL CHROMATOGRAPHIC SEPARATION CONDITIONS	08295119	8/24/1994	5,610,285	3/11/1997

PEPTIDE LIGANDS FOR AFFINITY PURIFICATION OF FIBRINOGEN	09012343	1/23/1998	5,783,663	7/21/1998
PEPTIDES WHICH BIND TO PROTHROMBIN AND THROMBIN	08672805	6/28/1996	5,831,003	11/3/1998
METHOD AND DEVICE FOR MECHANICAL TESTING OF FIBRIN GLUE STRENGTH	08864797	5/29/1997	5,911,165	6/8/1999
ALPHA-1 PROTEINASE INHIBITOR BINDING PEPTIDES	09127574	7/31/1998	5,985,836	11/16/1999
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF ACTIVE PLASMIN, PLASMIN FORMULATION AND PROCESS OF PRODUCING	09438331	11/13/1999	6,355,243	3/12/2002
METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR	09449695	11/24/1999	6,462,180	10/8/2002
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF REVERSIBLY INACTIVATED ACIDIFIED PLASMIN	10143157	5/10/2002	6,964,764	11/15/2005
METHOD OF THROMBOLYSIS BY LOCAL DELIVERY OF REVERSIBLY ACIDIFIED PLASMIN	10280444	10/25/2002	6,969,515	11/29/2005
PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION	10692105	10/23/2003	7,544,500	6/9/2009
REVERSIBLY INACTIVATED ACIDIFIED PLASMIN	12197617	8/25/2008	7,871,608	1/8/2011
METHOD FOR MELTING FROZEN, WATER-CONTAINING PRODUCTS IN A MIXER	10579401	2/1/2007	8,075,175	12/13/2011
RECOMBINANT PLASMIN FOR OPHTHALMIC INDICATIONS	12090782	3/23/2009	8,231,869	7/31/2012
METHOD OF TREATMENT AND PROPHYLAXIS OF DISEASES RELATED TO AMYLOID DEPOSITION USING IGM	12162532	5/7/2009	8,852,585	10/7/2014
METHOD COMPOSITION AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN	12741030	9/14/2010		
METHOD FOR ADJUSTING RESULTS OF A POLYMERASE CHAIN	12742801	9/14/2010	8,560,246	10/15/2013
RECOMBINANTLY MODIFIED PLASMIN	12744376	9/16/2010	8,101,394	1/24/2012
TWO-STAGE ULTRAFILTRATION / DIAFILTRATION	12937454	10/12/2010	8,772,461	7/8/2014
COMPOSITION, METHOD AND KIT FOR PREPARING PLASMIN	12995447	3/18/2011	8,617,863	12/31/2013
COMPOSITION, METHOD AND KIT FOR PREPARING PLASMINOGEN, AND PLASMIN DERIVED THEREFROM	13147491	9/23/2011	9,206,410	12/8/2015

COMPOSITION, METHOD AND KIT FOR PREPARING PLASMINOGEN, AND PLASMIN DERIVED THEREFROM	14819001	8/5/2015		
DEVICE FOR MAINTAINING STERILE INTEGRITY OF CONNECTED FLUID	13262269	12/16/2011	8,596,326	12/3/2013
COMPOSITION, METHOD, AND KIT FOR ALPHA-1 PROTEINASE INHIBITOR	14926450	10/29/2015		
VON WILLEBRAND FACTOR (VWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO	13509309	7/31/2012	8,759,293	6/24/2014
LYOPHILIZATION METHODS, COMPOSITIONS AND KITS	13510401	10/31/2012	8,648,177	2/11/2014
THERAPEUTIC DELIVERY DEVICES, SYSTEMS, AND METHODS	13581697	11/12/2012	8,840,637	9/23/2014
IMMUNOCHROMATOGRAPHY DEVICES, METHODS AND KITS	13823505	3/14/2013	9,121,857	9/1/2015
METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV)	14119563	11/22/2013	9,273,366	3/1/2016
COMPOSITIONS, METHODS, AND KITS FOR NUCLEIC ACID HYBRIDIZATION	14237746	6/5/2014	9,512,493	12/6/2016
REVERSIBLY INACTIVATED ACIDIFIED PLASMIN COMPOSITION	13761684	2/7/2013		
RECOMBINANTLY MODIFIED PLASMIN	13302322	11/22/2011	8,182,808	5/22/2012
METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR	15161931	5/23/2016		
IMMUNOCHROMATOGRAPHY DEVICES, METHODS, AND KITS	14803416	7/20/2015		
RECOMBINANTLY MODIFIED PLASMIN	11568023	2/1/2008	8,034,913	10/11/2011
PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION	12399438	3/6/2009	8,268,782	9/18/2012
RECOMBINANTLY MODIFIED PLASMIN	13223373	9/1/2011	8,420,079	4/16/2013
RECOMBINANTLY MODIFIED PLASMIN	13463437	5/3/2012	8,512,980	8/20/2013
TWO-STAGE ULTRAFILTRATION/DIAFILTRATION	14294460	6/3/2014		
METHODS, COMPOSITIONS, AND KITS FOR DETERMINING HUMAN IMMUNODEFICIENCY VIRUS (HIV)	14221341	3/21/2014		

METHOD OF USING PON-1 TO DECREASE ATHEROMA FORMATION	09199672	11/25/1998	6,391,298	5/21/2002
DEVICE AND METHOD FOR PRECIPITATION OF PEPTIDES	12520117	12/23/2009	8,232,369	7/31/2012 ¹
METHODS AND COMPOSITIONS FOR TREATING HERPES INFECTIONS	10656781	9/5/2003	6,984,492	1/10/2006
METHOD OF USING PON-1 TO DECREASE ATHEROMA FORMATION	10105640	03/25/2002	6,521,226	02/18/2003
METHODS FOR DETECTION OF PARVOVIRUS B19	14053245	10/14/2013	9,290,820	3/22/2016
DEVICE AND METHOD FOR DETECTING BLOOD GROUP ANTIGENS BY MEANS OF AN INCOMPLETE ANTIBODY	15312365	5/23/2015		
HUMAN ERYTHROVIRUS	12724032	3/15/2010		
HUMAN ERITROVIRUS	14288691	5/28/2014		
COMPOSITION COMPRISING HIGHLY CONCENTRATED ALPHA -1- PROTEINASE INHIBITOR AND METHOD FOR OBTAINING THEREOF	62442134	1/4/2017		

¹ Co-owned with Bayer Intellectual Property GmbH.